A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis

被引：0

作者：

Argyris Tzouvelekis

Vassilis Paspaliaris

George Koliakos

Paschalis Ntolios

Evangelos Bouros

Anastasia Oikonomou

Athanassios Zissimopoulos

Nikolaos Boussios

Brian Dardzinski

Dimitrios Gritzalis

Antonis Antoniadis

Marios Froudarakis

George Kolios

Demosthenes Bouros

机构：

[1] Democritus University of Thrace,Department of Pneumonology, Medical School

[2] Adistem Ltd,Laboratory of Pharmacology, Medical School

[3] Hellenic National research foundation stem cell bank,Department of Radiology, Medical School

[4] Biohellenika SA,Department of Nuclear Medicine, Medical School

[5] Democritus University of Thrace,Department of Pneumonology

[6] Democritus University of Thrace,Department of Pneumonology

[7] Democritus University of Thrace,undefined

[8] Iaso General Hospital,undefined

[9] General Hospital of Serres,undefined

[10] University Hospital of Alexandroupolis,undefined

[11] Democritus University of Thrace,undefined

来源：

Journal of Translational Medicine | / 11卷

关键词：

Adipose derived stromal cells; Mesenchymal stem cells; Idiopathic pulmonary fibrosis; Safety; Clinical trial; Stromal vascular fraction;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 344 条

[1] Wuyts WA(2013)The pathogenesis of pulmonary fibrosis: a moving target Eur Respir J 41 1207-1218
[2] Agostini C(2011)An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management Am J Respir Crit Care Med 183 788-824
[3] Antoniou K(2011)Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials Lancet 377 1760-1769
[4] Bouros D(2011)Pirfenidone for idiopathic pulmonary fibrosis Lancet 377 1727-1729
[5] Chambers R(2011)Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis N Engl J Med 365 1079-1087
[6] Cottin V(2006)Incidence and prevalence of idiopathic pulmonary fibrosis Am J Respir Crit Care Med 174 810-816
[7] Raghu G(2009)Improving the standard of care for patients with idiopathic pulmonary fibrosis requires participation in clinical trials Chest 136 330-333
[8] Collard HR(2010)Mesenchymal stem cells: biological properties and clinical applications Expert Opin Biol Ther 10 1453-1468
[9] Egan JJ(2007)New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis: a potential role for stem cells in the lung parenchyma and implications for therapy Pharm Res 24 819-841
[10] Martinez FJ(2011)Evidence for human lung stem cells N Engl J Med 364 1795-1806